8-K 1 f8k03m.txt IMMUNOTECH CURRENT REPORT 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 20, 2003 ------------------------------------------------- (Date of Report: Date of earliest event reported) IMMUNOTECHNOLOGY CORPORATION ------------------------------------------------------ (Exact name of registrant as specified in its charter) DELAWARE 0-24641 84-1016435 ---------------------------- ----------------------- -------------------- (State or other jurisdiction (Commission File Number) (IRS Employer ID No.) of incorporation) 1661 Lakeview Circle, Ogden, Utah 84403 ------------------------------------------------ (Address of principal executive office) Registrant's telephone number, including area code: (801) 399-3632 -------------- Not Applicable --------------------------------------------------------------------- (Former name or former address, if changed since last report) 2 ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE Letter of Intent to Acquire Ultimate Security Systems Corporation ----------------------------------------------------------------- On February 20, 2003, we executed a letter of intent to acquire 100% of the outstanding common stock of Ultimate Security Systems Corporation, a privately held Nevada corporation, for newly-issued shares of our capital stock. The terms of the letter of intent and the press release issued by the acquiree in connection with the proposed transaction have been attached as exhibits to this report and are incorporated herein by this reference. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS, AND EXHIBITS (c) Exhibits. The following exhibits are included as part of this report: SEC Exhibit Reference Number Number Title of Document Location ------- --------- ----------------- -------- 20.01 20 Press Release re: Letter of Intent This Filing 20.02 20 Letter of Intent, dated Feb. 20, 2003 This Filing SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized. IMMUNOTECHNOLOGY CORPORATION Date: March 7, 2003 /S/David Knudson, Secretary/Treasurer